Clinical Micro Sensors, Inc.

Nanogen has spent years developing gene-chip technology. Now it's trying to launch a system in a still-inchoate market that is chaotic, competitive and alluring. Deborah Erickson The promise of genomi

Dealmaking leverage lies with those with the power to either keep and profit from the status quo or remake it. For devices, the status quo prevailed; in pharmaceuticals, investors were eagerly awaitin

Motorola is developing an expertise in microarray manufacturing to use as the jump-off point for a new life sciences initiative it hopes will turn into a high-margin, high-growth diagnostics business.

In keeping with its open platform strategy, Incyte Genomics Inc. licensed its portfolio of proprietary gene sequences, including the LifeSeq Gold and ZooSeq databases, to Motorola Inc. 's Bio